Bachmann–Bupp Syndrome (BABS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Bachmann–Bupp Syndrome (BABS) Market Outlook

Thelansis’s “Bachmann–Bupp Syndrome (BABS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Bachmann–Bupp Syndrome (BABS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Bachmann–Bupp Syndrome (BABS) Overview

Bachmann–Bupp syndrome (BABS) is an autosomal dominant genetic disorder caused by heterozygous de novo gain-of function pathogenic variants in the ornithine decarboxylase 1 (ODC1) gene located on chromosome 2p25.1. These variants result in increased polyamines, causing abnormalities of functions such as angiogenesis, carcinogenesis, and embryogenesis. Currently, there are nine humans reported having ODC1 pathogenic variants. Features which are shared amongst these individuals include polyhydramnios, broad forehead/macrocephaly, neuroimaging abnormalities with no particular pattern, global developmental delay, cryptorchidism in male patients, and muscular hypotonia. The patient presented at 11 months of age with near-total alopecia of the scalp, eyebrows, eyelashes and curved, brittle fingernails. Around age one year, she started developing pustules and cysts on the posterior scalp and back. Five larger lesions became erythematous and tender, resulting in rupture and ultimately requiring excision.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Bachmann–Bupp Syndrome (BABS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034